Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Dexmedetomidine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Dexmedetomidine | hsa00052 | Galactose metabolism | 4.27E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Dexmedetomidine | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Dexmedetomidine | hsa00220 | Arginine biosynthesis | 1.26E-03 | 3 | P15104, P05089, P49448 | GLUL, ARG1, GLUD2 | More | | Dexmedetomidine | hsa00250 | Alanine, aspartate and glutamate metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | Dexmedetomidine | hsa00500 | Starch and sucrose metabolism | 8.96E-06 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Dexmedetomidine | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.24E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Dexmedetomidine | hsa00531 | Glycosaminoglycan degradation | 8.18E-04 | 2 | P15586, P34059 | GNS, GALNS | More | | Dexmedetomidine | hsa00532 | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 2.92E-02 | 1 | Q9Y2C2 | UST | More | | Dexmedetomidine | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Dexmedetomidine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Dexmedetomidine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Dexmedetomidine | hsa00730 | Thiamine metabolism | 1.44E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Dexmedetomidine | hsa00750 | Vitamin B6 metabolism | 3.56E-02 | 1 | O00764 | PDXK | More | | Dexmedetomidine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Dexmedetomidine | hsa00830 | Retinol metabolism | 2.51E-03 | 4 | P00325, P00352, Q9BPW9, O75911 | ADH1B, ALDH1A1, DHRS9, DHRS3 | More | | Dexmedetomidine | hsa00910 | Nitrogen metabolism | 2.42E-02 | 1 | P15104 | GLUL | More | | Dexmedetomidine | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.41E-04 | 3 | O95363, P54136, P14868 | FARS2, RARS1, DARS | More | | Dexmedetomidine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Dexmedetomidine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Dexmedetomidine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Dexmedetomidine | hsa01210 | 2-Oxocarboxylic acid metabolism | 3.56E-02 | 1 | P50213 | IDH3A | More | | Dexmedetomidine | hsa01230 | Biosynthesis of amino acids | 1.16E-03 | 4 | P51854, P60891, P15104, P37837 | TKTL1, PRPS1, GLUL, TALDO1 | More | | Dexmedetomidine | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | | Dexmedetomidine | hsa01524 | Platinum drug resistance | 4.78E-02 | 1 | P31751 | AKT2 | More | | Dexmedetomidine | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | | Dexmedetomidine | hsa03008 | Ribosome biogenesis in eukaryotes | 1.34E-03 | 3 | Q9NYH9, P78345, Q9BVP2 | UTP6, RPP38, GNL3 | More | | Dexmedetomidine | hsa03013 | RNA transport | 4.92E-03 | 10 | P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | | Dexmedetomidine | hsa03015 | mRNA surveillance pathway | 1.83E-02 | 3 | Q13362, Q14738, Q9UBU9 | PPP2R5C, PPP2R5D, NXF1 | More | | Dexmedetomidine | hsa03020 | RNA polymerase | 9.80E-05 | 2 | Q9GZM3, P52435 | POLR2J2, POLR2J | More | | Dexmedetomidine | hsa03050 | Proteasome | 9.60E-03 | 2 | P55036, P28074 | PSMD4, PSMB5 | More | | Dexmedetomidine | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Dexmedetomidine | hsa04014 | Ras signaling pathway | 7.30E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Dexmedetomidine | hsa04015 | Rap1 signaling pathway | 6.14E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Dexmedetomidine | hsa04022 | cGMP-PKG signaling pathway | 5.07E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Dexmedetomidine | hsa04024 | cAMP signaling pathway | 3.23E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Dexmedetomidine | hsa04060 | Cytokine-cytokine receptor interaction | 5.34E-03 | 11 | P14784, P27930, P14778, P26842, Q06643, Q13651, P25024, Q9UBD3, P47992, P09341, P01730 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL10RA, CXCR1, XCL2, XCL1, CXCL1, CD4 | More | | Dexmedetomidine | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.13E-03 | 8 | P09341, P25024, P25025, P47992, Q9UBD3, Q13651, P14784, P01375 | CXCL1, CXCR1, CXCR2, XCL1, XCL2, IL10RA, IL2RB, TNF | More | | Dexmedetomidine | hsa04062 | Chemokine signaling pathway | 6.73E-03 | 9 | P25024, P09341, P47992, Q9UBD3, P07948, P63218, P50151, P43250, Q08881 | CXCR1, CXCL1, XCL1, XCL2, LYN, GNG5, GNG10, GRK6, ITK | More | | Dexmedetomidine | hsa04064 | NF-kappa B signaling pathway | 4.91E-06 | 17 | P10415, Q13489, P25963, P51617, O00463, P14778, P01375, Q04759, Q9UDY8, Q13077, Q16548, P07948, P06239, Q13315, P24522, P09341, Q06643 | BCL2, BIRC3, NFKBIA, IRAK1, TRAF5, IL1R1, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, LYN, LCK, ATM, GADD45A, CXCL1, LTB | More | | Dexmedetomidine | hsa04071 | Sphingolipid signaling pathway | 5.48E-06 | 8 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2 | More | | Dexmedetomidine | hsa04080 | Neuroactive ligand-receptor interaction | 3.10E-05 | 12 | P08311, P28472, Q15722, P21453, Q9H228, P43657, O00398, P21462, P21730, P14416, P07550, P35318 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY5, P2RY10, FPR1, C5AR1, DRD2, ADRB2, ADM | More | | Dexmedetomidine | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | | Dexmedetomidine | hsa04114 | Oocyte meiosis | 1.25E-03 | 7 | P51812, Q02750, P0DP23, P16298, Q17RY0, Q13362, Q14738 | RPS6KA3, MAP2K1, CALM1, PPP3CB, CPEB4, PPP2R5C, PPP2R5D | More | | Dexmedetomidine | hsa04115 | p53 signaling pathway | 3.57E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | Dexmedetomidine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Dexmedetomidine | hsa04142 | Lysosome | 1.12E-03 | 5 | Q99437, P43234, P25774, P15586, P34059 | ATP6V0B, CTSO, CTSS, GNS, GALNS | More | | Dexmedetomidine | hsa04145 | Phagosome | 7.50E-03 | 10 | Q15080, P14598, Q13509, Q13488, Q99437, P05164, O60603, P35443, P13765, P25774 | NCF4, NCF1, TUBB3, TCIRG1, ATP6V0B, MPO, TLR2, THBS4, HLA-DOB, CTSS | More | | Dexmedetomidine | hsa04146 | Peroxisome | 2.42E-02 | 5 | O43933, P56589, Q9UKG9, O75521, P33121 | PEX1, PEX3, CROT, ECI2, ACSL1 | More | | Dexmedetomidine | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | Dexmedetomidine | hsa04152 | AMPK signaling pathway | 1.83E-02 | 3 | Q96RR4, Q13362, Q14738 | CAMKK2, PPP2R5C, PPP2R5D | More | | Dexmedetomidine | hsa04210 | Apoptosis | 1.42E-03 | 12 | Q13315, P04637, P10415, Q13489, P25963, P01375, P24522, Q16548, Q13077, P43234, Q14643, P63261 | ATM, TP53, BCL2, BIRC3, NFKBIA, TNF, GADD45A, BCL2A1, TRAF1, CTSO, ITPR1, ACTG1 | More | | Dexmedetomidine | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | | Dexmedetomidine | hsa04218 | Cellular senescence | 2.09E-03 | 6 | P01106, P31751, O75293, P30304, P06493, P0DP23 | MYC, AKT2, GADD45B, CDC25A, CDK1, CALM1 | More | | Dexmedetomidine | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.26E-04 | 7 | P07550, P22694, P31751, P18848, Q13362, Q14738, P0DP23 | ADRB2, PRKACB, AKT2, ATF4, PPP2R5C, PPP2R5D, CALM1 | More | | Dexmedetomidine | hsa04340 | Hedgehog signaling pathway | 3.46E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | Dexmedetomidine | hsa04360 | Axon guidance | 1.66E-02 | 3 | P20827, P23528, Q06124 | EFNA1, CFL1, PTPN11 | More | | Dexmedetomidine | hsa04370 | VEGF signaling pathway | 3.03E-04 | 4 | P16298, P31751, Q05397, Q02750 | PPP3CB, AKT2, PTK2, MAP2K1 | More | | Dexmedetomidine | hsa04371 | Apelin signaling pathway | 3.23E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Dexmedetomidine | hsa04380 | Osteoclast differentiation | 2.72E-04 | 8 | Q9NQC7, Q9UQC2, Q16539, P31751, P14778, O75015, P01375, Q8N149 | CYLD, GAB2, MAPK14, AKT2, IL1R1, FCGR3B, TNF, LILRA2 | More | | Dexmedetomidine | hsa04390 | Hippo signaling pathway | 2.30E-02 | 3 | P63261, P04628, O43623 | ACTG1, WNT1, SNAI2 | More | | Dexmedetomidine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Dexmedetomidine | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.96E-02 | 3 | P04628, P40189, P14653 | WNT1, IL6ST, HOXB1 | More | | Dexmedetomidine | hsa04610 | Complement and coagulation cascades | 1.29E-05 | 2 | P00734, P0C0L4 | F2, C4A | More | | Dexmedetomidine | hsa04612 | Antigen processing and presentation | 4.86E-07 | 10 | P13765, P48382, P01730, Q14953, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, CD4, KIR2DS5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P14780 | MMP9 | Matrix metalloproteinase-9 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.714 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P48382 | RFX5 | DNA-binding protein RFX5 | -0.747 | P14780 | MMP9 | Matrix metalloproteinase-9 | P48382 | RFX5 | DNA-binding protein RFX5 | -0.874 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 | P14780 | MMP9 | Matrix metalloproteinase-9 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.867 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | P14780 | MMP9 | Matrix metalloproteinase-9 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.867 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.719 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.837 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | O43908 | KLRC4 | NKG2-F type II integral membrane protein | -0.718 | P14780 | MMP9 | Matrix metalloproteinase-9 | O43908 | KLRC4 | NKG2-F type II integral membrane protein | -0.792 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.704 | P14780 | MMP9 | Matrix metalloproteinase-9 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.742 | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.812 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P01375 | TNF | Tumor necrosis factor | 0.761 | P14780 | MMP9 | Matrix metalloproteinase-9 | P01375 | TNF | Tumor necrosis factor | 0.897 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 |
| Dexmedetomidine | hsa04613 | Neutrophil extracellular trap formation | 3.26E-08 | 21 | P17252, O60603, P05164, P08246, Q9UM07, Q13547, Q6FI13, Q93077, P62807, O60814, P68431, P14598, Q15080, P20160, P08311, P49913, O75015, P21730, P21462, O43315, Q16539 | PRKCA, TLR2, MPO, ELA2, PADI4, HDAC1, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, AZU1, CTSG, CAMP, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P08246 | ELA2 | Neutrophil elastase | P17252 | PRKCA | Protein kinase C alpha type | -0.735 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | O60603 | TLR2 | Toll-like receptor 2 | 0.762 | P14780 | MMP9 | Matrix metalloproteinase-9 | O60603 | TLR2 | Toll-like receptor 2 | 0.89 | P08246 | ELA2 | Neutrophil elastase | O60603 | TLR2 | Toll-like receptor 2 | 0.853 | P22748 | CA4 | Carbonic anhydrase 4 | O60603 | TLR2 | Toll-like receptor 2 | 0.919 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P05164 | MPO | Myeloperoxidase | 0.717 | P14780 | MMP9 | Matrix metalloproteinase-9 | P05164 | MPO | Myeloperoxidase | 0.812 | P08246 | ELA2 | Neutrophil elastase | P05164 | MPO | Myeloperoxidase | 0.903 | P22748 | CA4 | Carbonic anhydrase 4 | P05164 | MPO | Myeloperoxidase | 0.826 | P14780 | MMP9 | Matrix metalloproteinase-9 | P08246 | ELA2 | Neutrophil elastase | 0.859 | P08246 | ELA2 | Neutrophil elastase | P08246 | ELA2 | Neutrophil elastase | 1 | P22748 | CA4 | Carbonic anhydrase 4 | P08246 | ELA2 | Neutrophil elastase | 0.921 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.736 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.9 | P08246 | ELA2 | Neutrophil elastase | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.889 | P22748 | CA4 | Carbonic anhydrase 4 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.856 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.759 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q6FI13 | H2AC18; H2AC19 | Histone H2A type 2-A | 0.74 | P08246 | ELA2 | Neutrophil elastase | Q6FI13 | H2AC18; H2AC19 | Histone H2A type 2-A | 0.907 | P22748 | CA4 | Carbonic anhydrase 4 | Q6FI13 | H2AC18; H2AC19 | Histone H2A type 2-A | 0.866 | P11712 | CYP2C9 | Cytochrome P450 2C9 | Q93077 | HIST1H2AC | Histone H2A type 1-C | 0.754 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.717 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.717 | P11712 | CYP2C9 | Cytochrome P450 2C9 | O60814 | H2BC12 | Histone H2B type 1-K | 0.728 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P68431 | H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | Histone H3.1 | 0.845 | P08246 | ELA2 | Neutrophil elastase | P14598 | NCF1 | Neutrophil cytosol factor 1 | 0.762 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.706 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.869 | P08246 | ELA2 | Neutrophil elastase | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.945 | P22748 | CA4 | Carbonic anhydrase 4 | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.951 | P14780 | MMP9 | Matrix metalloproteinase-9 | P20160 | AZU1 | Azurocidin | 0.734 | P08246 | ELA2 | Neutrophil elastase | P20160 | AZU1 | Azurocidin | 0.842 | P22748 | CA4 | Carbonic anhydrase 4 | P20160 | AZU1 | Azurocidin | 0.747 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P08311 | CTSG | Cathepsin G | 0.715 | P14780 | MMP9 | Matrix metalloproteinase-9 | P08311 | CTSG | Cathepsin G | 0.79 | P08246 | ELA2 | Neutrophil elastase | P08311 | CTSG | Cathepsin G | 0.792 | P22748 | CA4 | Carbonic anhydrase 4 | P08311 | CTSG | Cathepsin G | 0.717 | P08246 | ELA2 | Neutrophil elastase | P49913 | CAMP | Cathelicidin antimicrobial peptide | 0.807 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.892 | P14780 | MMP9 | Matrix metalloproteinase-9 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.928 | P22748 | CA4 | Carbonic anhydrase 4 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.81 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 0.923 | P14780 | MMP9 | Matrix metalloproteinase-9 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 0.942 | P08246 | ELA2 | Neutrophil elastase | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 0.703 | P22748 | CA4 | Carbonic anhydrase 4 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 0.826 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.779 | P14780 | MMP9 | Matrix metalloproteinase-9 | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.912 | P08246 | ELA2 | Neutrophil elastase | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.85 | P22748 | CA4 | Carbonic anhydrase 4 | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.895 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | O43315 | AQP9 | Aquaporin-9 | 0.918 | P14780 | MMP9 | Matrix metalloproteinase-9 | O43315 | AQP9 | Aquaporin-9 | 0.837 | P22748 | CA4 | Carbonic anhydrase 4 | O43315 | AQP9 | Aquaporin-9 | 0.771 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.839 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.778 | P22748 | CA4 | Carbonic anhydrase 4 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.767 |
| Dexmedetomidine | hsa04620 | Toll-like receptor signaling pathway | 4.78E-02 | 1 | P31751 | AKT2 | More | | Dexmedetomidine | hsa04621 | NOD-like receptor signaling pathway | 2.68E-04 | 14 | Q16539, Q14643, P25963, Q13489, P10599, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P09341, P49913, P12838 | MAPK14, ITPR1, NFKBIA, BIRC3, TXN, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CXCL1, CAMP, DEFA4 | More | | Dexmedetomidine | hsa04622 | RIG-I-like receptor signaling pathway | 1.81E-02 | 1 | Q9NQC7 | CYLD | More | | Dexmedetomidine | hsa04625 | C-type lectin receptor signaling pathway | 2.27E-04 | 7 | Q9ULY5, Q9NQC7, P20749, P01375, P31751, P0DP23, Q16539 | CLEC4E, CYLD, BCL3, TNF, AKT2, CALM1, MAPK14 | More | | Dexmedetomidine | hsa04630 | JAK-STAT signaling pathway | 4.43E-02 | 3 | P48551, P40189, Q06124 | IFNAR2, IL6ST, PTPN11 | More | | Dexmedetomidine | hsa04640 | Hematopoietic cell lineage | 2.49E-05 | 11 | P13612, P21926, P14778, P27930, P25063, P07766, P09693, P01732, P01730, P09564, P13765 | ITGA4, CD9, IL1R1, IL1R2, CD24, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB | More | | Dexmedetomidine | hsa04650 | Natural killer cell mediated cytotoxicity | 3.97E-09 | 15 | P16298, P50591, P01375, P78314, P06239, O60880, P20963, Q02750, Q13241, P26718, O14931, O75015, P26717, Q14953, P26715 | PPP3CB, TNFSF10, TNF, SH3BP2, LCK, SH2D1A, CD247, MAP2K1, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P11511 | CYP19A1 | Aromatase | P16298 | PPP3CB | Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform | 0.706 | P11511 | CYP19A1 | Aromatase | P50591 | TNFSF10 | Tumor necrosis factor ligand superfamily member 10 | 0.701 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P01375 | TNF | Tumor necrosis factor | 0.761 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.718 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P06239 | LCK | Tyrosine-protein kinase Lck | -0.709 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.786 | P06239 | LCK | Tyrosine-protein kinase Lck | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.906 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.764 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.707 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | P11511 | CYP19A1 | Aromatase | Q02750 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 0.783 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.719 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.773 | P06239 | LCK | Tyrosine-protein kinase Lck | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.886 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.803 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.732 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.892 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.81 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 |
| Dexmedetomidine | hsa04657 | IL-17 signaling pathway | 2.36E-06 | 9 | O00463, Q16539, P49841, P09341, P19875, P14780, Q9UJX4, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, ANAPC5, LCN2, TNF | More | | Dexmedetomidine | hsa04658 | Th1 and Th2 cell differentiation | 4.07E-09 | 13 | Q04759, P07766, P20963, P09693, Q16539, P01730, P06239, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, CD4, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P14780 | MMP9 | Matrix metalloproteinase-9 | Q04759 | PRKCQ | Protein kinase C theta type | -0.787 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P14780 | MMP9 | Matrix metalloproteinase-9 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.745 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.703 | P14780 | MMP9 | Matrix metalloproteinase-9 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.719 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.734 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.778 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.901 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P06239 | LCK | Tyrosine-protein kinase Lck | -0.709 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | -0.861 | P14780 | MMP9 | Matrix metalloproteinase-9 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.747 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.808 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.73 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | P14780 | MMP9 | Matrix metalloproteinase-9 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.714 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | P05186 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.731 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.85 |
| Dexmedetomidine | hsa04659 | Th17 cell differentiation | 2.51E-07 | 12 | Q04759, Q16539, P01730, P06239, P14784, P13765, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, MAPK14, CD4, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | | Dexmedetomidine | hsa04660 | T cell receptor signaling pathway | 2.43E-06 | 16 | P01375, P25963, Q9UDY8, Q04759, P10747, O95267, Q08881, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | TNF, NFKBIA, MALT1, PRKCQ, CD28, RASGRP1, ITK, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Dexmedetomidine | hsa04662 | B cell receptor signaling pathway | 4.78E-02 | 1 | P31751 | AKT2 | More | | Dexmedetomidine | hsa04664 | Fc epsilon RI signaling pathway | 9.49E-03 | 4 | P01375, P31751, Q16539, Q9UQC2 | TNF, AKT2, MAPK14, GAB2 | More | | Dexmedetomidine | hsa04668 | TNF signaling pathway | 2.13E-04 | 10 | P01375, O00463, Q13489, Q16539, P25963, P18848, P19875, P20749, Q13077, P14780 | TNF, TRAF5, BIRC3, MAPK14, NFKBIA, ATF4, CXCL2, BCL3, TRAF1, MMP9 | More | | Dexmedetomidine | hsa04670 | Leukocyte transendothelial migration | 4.20E-02 | 7 | P14780, Q96A32, P17252, P14598, Q15080, Q08881, P42681 | MMP9, MYLPF, PRKCA, NCF1, NCF4, ITK, TXK | More | | Dexmedetomidine | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | Dexmedetomidine | hsa04722 | Neurotrophin signaling pathway | 1.26E-03 | 5 | P31751, P49841, O43524, P48023, P0DP23 | AKT2, GSK3B, FOXO3, FASLG, CALM1 | More | | Dexmedetomidine | hsa04728 | Dopaminergic synapse | 7.72E-04 | 4 | P31751, Q13362, Q14738, P0DP23 | AKT2, PPP2R5C, PPP2R5D, CALM1 | More | | Dexmedetomidine | hsa04740 | Olfactory transduction | 9.46E-04 | 2 | Q9H255, P0DP23 | OR51E2, CALM1 | More | | Dexmedetomidine | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | Dexmedetomidine | hsa04744 | Phototransduction | 1.81E-02 | 1 | P0DP23 | CALM1 | More | | Dexmedetomidine | hsa04910 | Insulin signaling pathway | 9.82E-04 | 2 | P0DP23, P31751 | CALM1, AKT2 | More | | Dexmedetomidine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Dexmedetomidine | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | | Dexmedetomidine | hsa04915 | Estrogen signaling pathway | 5.07E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Dexmedetomidine | hsa04916 | Melanogenesis | 4.78E-02 | 1 | P0DP23 | CALM1 | More | | Dexmedetomidine | hsa04917 | Prolactin signaling pathway | 2.41E-02 | 1 | P31751 | AKT2 | More | | Dexmedetomidine | hsa04920 | Adipocytokine signaling pathway | 1.22E-02 | 5 | P25963, P33121, Q04759, P31751, P01375 | NFKBIA, ACSL1, PRKCQ, AKT2, TNF | More | | Dexmedetomidine | hsa04921 | Oxytocin signaling pathway | 3.13E-02 | 3 | P0DP23, Q96RR4, Q13469 | CALM1, CAMKK2, NFATC2 | More | | Dexmedetomidine | hsa04922 | Glucagon signaling pathway | 1.79E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Dexmedetomidine | hsa04923 | Regulation of lipolysis in adipocytes | 3.01E-02 | 1 | P31751 | AKT2 | More | | Dexmedetomidine | hsa04924 | Renin secretion | 6.02E-03 | 3 | P22694, P07550, P0DP23 | PRKACB, ADRB2, CALM1 | More | | Dexmedetomidine | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Dexmedetomidine | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Dexmedetomidine | hsa04929 | GnRH secretion | 1.81E-02 | 1 | P31751 | AKT2 | More | | Dexmedetomidine | hsa04932 | Non-alcoholic fatty liver disease | 2.74E-02 | 3 | P01375, P49841, P48023 | TNF, GSK3B, FASLG | More | | Dexmedetomidine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Dexmedetomidine | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | Dexmedetomidine | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | | Dexmedetomidine | hsa04970 | Salivary secretion | 6.99E-04 | 6 | P07550, P22694, Q14643, P17252, P0DP23, P49913 | ADRB2, PRKACB, ITPR1, PRKCA, CALM1, CAMP | More | | Dexmedetomidine | hsa04971 | Gastric acid secretion | 4.78E-02 | 1 | P0DP23 | CALM1 | More | | Dexmedetomidine | hsa04973 | Carbohydrate digestion and absorption | 2.41E-02 | 1 | P31751 | AKT2 | More | | Dexmedetomidine | hsa04976 | Bile secretion | 3.87E-02 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | | Dexmedetomidine | hsa04979 | Cholesterol metabolism | 1.61E-02 | 2 | P38571, P61916 | LIPA, NPC2 | More | | Dexmedetomidine | hsa05010 | Alzheimer disease | 8.59E-04 | 3 | Q00535, P0DP23, P31751 | CDK5, CALM1, AKT2 | More | | Dexmedetomidine | hsa05016 | Huntington disease | 1.07E-02 | 3 | Q9GZM3, P52435, P55036 | POLR2J2, POLR2J, PSMD4 | More | | Dexmedetomidine | hsa05017 | Spinocerebellar ataxia | 2.43E-02 | 1 | P28074 | PSMB5 | More | | Dexmedetomidine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.95E-02 | 2 | Q00535, P0DP23 | CDK5, CALM1 | More | | Dexmedetomidine | hsa05030 | Cocaine addiction | 4.19E-02 | 1 | Q00535 | CDK5 | More | | Dexmedetomidine | hsa05031 | Amphetamine addiction | 6.98E-03 | 4 | P0DP23, P22694, P18848, Q13547 | CALM1, PRKACB, ATF4, HDAC1 | More | | Dexmedetomidine | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Dexmedetomidine | hsa05110 | Vibrio cholerae infection | 4.78E-02 | 1 | Q99437 | ATP6V0B | More | | Dexmedetomidine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.87E-02 | 4 | Q16539, P09341, P25024, P25025 | MAPK14, CXCL1, CXCR1, CXCR2 | More | | Dexmedetomidine | hsa05131 | Shigellosis | 3.34E-02 | 11 | P01375, P25963, O00463, Q04759, Q9UDY8, Q9H1Y0, Q14643, Q12778, Q13315, P10415, Q96A32 | TNF, NFKBIA, TRAF5, PRKCQ, MALT1, ATG5, ITPR1, FOXO1, ATM, BCL2, MYLPF | More | | Dexmedetomidine | hsa05132 | Salmonella infection | 2.98E-02 | 11 | P51617, P25963, P01375, Q9UJU2, Q13489, P10415, Q96A32, O60603, Q9BQS8, Q13561, Q13509 | IRAK1, NFKBIA, TNF, LEF1, BIRC3, BCL2, MYLPF, TLR2, FYCO1, DCTN2, TUBB3 | More | | Dexmedetomidine | hsa05133 | Pertussis | 2.64E-03 | 2 | P0DP23, P0C0L4 | CALM1, C4A | More | | Dexmedetomidine | hsa05140 | Leishmaniasis | 1.10E-04 | 10 | P13612, O75015, P14598, P13765, O60603, P25963, P01375, Q16539, P51617, Q15080 | ITGA4, FCGR3B, NCF1, HLA-DOB, TLR2, NFKBIA, TNF, MAPK14, IRAK1, NCF4 | More | | Dexmedetomidine | hsa05143 | African trypanosomiasis | 1.11E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | Dexmedetomidine | hsa05144 | Malaria | 6.46E-06 | 7 | P60033, P69905, P68871, O60603, P01375, P35443, P26718 | CD81, HBA2, HBB, TLR2, TNF, THBS4, KLRK1 | More | | Dexmedetomidine | hsa05145 | Toxoplasmosis | 3.07E-02 | 7 | P51617, P25963, P01375, P10415, Q13489, P13765, O60603 | IRAK1, NFKBIA, TNF, BCL2, BIRC3, HLA-DOB, TLR2 | More | | Dexmedetomidine | hsa05146 | Amoebiasis | 6.20E-07 | 11 | P09341, P19875, P14778, P27930, P01375, O60603, P05089, P30679, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | | Dexmedetomidine | hsa05152 | Tuberculosis | 2.24E-03 | 13 | Q13488, Q99437, P0DP23, P48382, O60603, P01375, P31751, P10415, P13765, P25774, P49913, Q9UDY8, P51617 | TCIRG1, ATP6V0B, CALM1, RFX5, TLR2, TNF, AKT2, BCL2, HLA-DOB, CTSS, CAMP, MALT1, IRAK1 | More | | Dexmedetomidine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Dexmedetomidine | hsa05161 | Hepatitis B | 2.33E-02 | 8 | P17252, P14780, P25963, P01375, P10415, P51617, O60603, Q14765 | PRKCA, MMP9, NFKBIA, TNF, BCL2, IRAK1, TLR2, STAT4 | More | | Dexmedetomidine | hsa05163 | Human cytomegalovirus infection | 8.39E-03 | 8 | P31751, P01375, P0DP23, P49841, P14778, P25025, Q16539, O00463 | AKT2, TNF, CALM1, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5 | More | | Dexmedetomidine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.44E-04 | 8 | P31751, P23458, P62879, Q13469, P16298, Q02750, P0DP23, P0CG47 | AKT2, JAK1, GNB2, NFATC2, PPP3CB, MAP2K1, CALM1, UBB | More | | Dexmedetomidine | hsa05169 | Epstein-Barr virus infection | 7.82E-04 | 12 | P13765, P01106, Q13547, O00463, Q16539, P07948, Q13761, P24522, O60603, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, TRAF5, MAPK14, LYN, RUNX3, GADD45A, TLR2, CD3E, CD3G, CD247 | More | | Dexmedetomidine | hsa05170 | Human immunodeficiency virus 1 infection | 2.37E-06 | 20 | P31751, Q02750, P62879, P16298, P0DP23, P01375, Q05397, P17252, O00463, Q14643, P51617, P25963, O60603, Q13315, O95067, P10415, Q13619, Q93034, Q9Y6Q5, P20333 | AKT2, MAP2K1, GNB2, PPP3CB, CALM1, TNF, PTK2, PRKCA, TRAF5, ITPR1, IRAK1, NFKBIA, TLR2, ATM, CCNB2, BCL2, CUL4A, CUL5, AP1M2, TNFRSF1B | More | | Dexmedetomidine | hsa05200 | Pathways in cancer | 3.07E-02 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Dexmedetomidine | hsa05202 | Transcriptional misregulation in cancer | 1.07E-06 | 20 | Q12778, Q15532, Q13315, P41732, P14780, P27930, P14923, Q15744, Q16548, Q13489, Q13077, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P12980, P24522 | FOXO1, SS18, ATM, TSPAN7, MMP9, IL1R2, JUP, CEBPE, BCL2A1, BIRC3, TRAF1, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, LYL1, GADD45A | More | | Dexmedetomidine | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Dexmedetomidine | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Dexmedetomidine | hsa05205 | Proteoglycans in cancer | 4.79E-03 | 8 | P63261, P04637, P14780, P01375, P23588, Q06124, Q13635, P22694 | ACTG1, TP53, MMP9, TNF, EIF4B, PTPN11, PTCH1, PRKACB | More | | Dexmedetomidine | hsa05211 | Renal cell carcinoma | 1.47E-03 | 3 | Q06124, Q99814, P31751 | PTPN11, EPAS1, AKT2 | More | | Dexmedetomidine | hsa05212 | Pancreatic cancer | 3.61E-04 | 5 | P31751, Q15311, P23458, P04637, P24522 | AKT2, RALBP1, JAK1, TP53, GADD45A | More | | Dexmedetomidine | hsa05213 | Endometrial cancer | 2.88E-04 | 5 | O15169, P31751, Q02750, P04637, P24522 | AXIN1, AKT2, MAP2K1, TP53, GADD45A | More | | Dexmedetomidine | hsa05214 | Glioma | 1.51E-04 | 4 | P0DP23, P31751, P04637, P24522 | CALM1, AKT2, TP53, GADD45A | More | | Dexmedetomidine | hsa05216 | Thyroid cancer | 1.08E-03 | 4 | P01106, P04637, P24522, O75293 | MYC, TP53, GADD45A, GADD45B | More | | Dexmedetomidine | hsa05217 | Basal cell carcinoma | 2.06E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | | Dexmedetomidine | hsa05218 | Melanoma | 8.68E-04 | 3 | P04637, P31751, P24522 | TP53, AKT2, GADD45A | More | | Dexmedetomidine | hsa05220 | Chronic myeloid leukemia | 5.62E-04 | 4 | Q06124, P04637, P31751, P24522 | PTPN11, TP53, AKT2, GADD45A | More | | Dexmedetomidine | hsa05221 | Acute myeloid leukemia | 4.19E-02 | 1 | P31751 | AKT2 | More | | Dexmedetomidine | hsa05222 | Small cell lung cancer | 5.10E-03 | 7 | P31751, Q13489, P10415, P25963, Q13077, O00463, P24522 | AKT2, BIRC3, BCL2, NFKBIA, TRAF1, TRAF5, GADD45A | More | | Dexmedetomidine | hsa05223 | Non-small cell lung cancer | 6.59E-05 | 6 | P31751, P10826, Q9HC35, P04637, P24522, O75293 | AKT2, RARB, EML4, TP53, GADD45A, GADD45B | More | | Dexmedetomidine | hsa05224 | Breast cancer | 4.51E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | | Dexmedetomidine | hsa05225 | Hepatocellular carcinoma | 3.30E-02 | 3 | P04637, P24522, P63261 | TP53, GADD45A, ACTG1 | More | | Dexmedetomidine | hsa05226 | Gastric cancer | 4.72E-03 | 3 | Q02750, P31751, O15169 | MAP2K1, AKT2, AXIN1 | More | | Dexmedetomidine | hsa05230 | Central carbon metabolism in cancer | 4.78E-02 | 1 | P31751 | AKT2 | More | | Dexmedetomidine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 5.29E-05 | 9 | P07766, P20963, P09693, P06239, O60603, Q04759, Q16539, Q9HC35, P01730 | CD3E, CD247, CD3G, LCK, TLR2, PRKCQ, MAPK14, EML4, CD4 | More | | Dexmedetomidine | hsa05310 | Asthma | 3.11E-03 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Dexmedetomidine | hsa05321 | Inflammatory bowel disease | 9.74E-06 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Dexmedetomidine | hsa05322 | Systemic lupus erythematosus | 2.09E-04 | 12 | P08246, P08311, P09871, P01375, P10747, P13765, Q6FI13, Q93077, P62807, O60814, P68431, P05455 | ELA2, CTSG, C1S, TNF, CD28, HLA-DOB, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, SSB | More | | Dexmedetomidine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Dexmedetomidine | hsa05332 | Graft-versus-host disease | 4.57E-07 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | | Dexmedetomidine | hsa05340 | Primary immunodeficiency | 1.31E-04 | 5 | P01730, P01732, P11912, P07766, P06239 | CD4, CD8A, CD79A, CD3E, LCK | More | | Dexmedetomidine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | Dexmedetomidine | hsa05416 | Viral myocarditis | 2.30E-02 | 2 | P10747, P63261 | CD28, ACTG1 | More | | Dexmedetomidine | hsa05418 | Fluid shear stress and atherosclerosis | 3.33E-05 | 9 | Q16539, P31751, Q14145, P10599, P14780, P01375, P14778, P27930, P0DP23 | MAPK14, AKT2, KEAP1, TXN, MMP9, TNF, IL1R1, IL1R2, CALM1 | More | | |